Shorts On Watch: Could Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Go Up After Its Newest Short Interest Report?

November 30, 2016 - By Marie Mckinney   ·   0 Comments

Shorts On Watch: Could Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Go Up After Its Newest Short Interest Report?

The stock of Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) registered an increase of 36.66% in short interest. CYCC’s total short interest was 231,500 shares in November as published by FINRA. Its up 36.66% from 169,400 shares, reported previously. With 101,500 shares average volume, it will take short sellers 2 days to cover their CYCC’s short positions. About 71,550 shares traded hands. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has declined 21.32% since April 27, 2016 and is downtrending. It has underperformed by 26.54% the S&P500.

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The company has a market cap of $15.74 million. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. It currently has negative earnings. The Company’s family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065.

Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 0.09, from 0.09 in 2016Q1. The ratio turned negative, as 23 funds sold all Cyclacel Pharmaceuticals Inc shares owned while 0 reduced positions. 2 funds bought stakes while 0 increased positions. They now own 13,631 shares or 99.80% less from 6.70 million shares in 2016Q1.
Tower Research Ltd Llc (Trc) last reported 378 shares in the company. Baker Bros Advsr Lp holds 13,253 shares or 0% of its portfolio.

CYCC Company Profile

Cyclacel Pharmaceuticals, Inc., incorporated on January 5, 1996, operates in the field of cell cycle biology. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Company’s family of anticancer drugs acts on the cell cycle.

More important recent Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on September 11, 2009, also Investorplace.com published article titled: “Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype”, Seekingalpha.com published: “Cyclacel Pharmaceuticals, Inc.’s (CYCC) CEO Spiro Rombotis on Q2 2016 Results …” on August 10, 2016. More interesting news about Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) was released by: Quotes.Wsj.com and their article: “News Cyclacel Pharmaceuticals Inc.CYCC” with publication date: February 11, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>